Sleep Cycle AB (publ)

Informe acción OM:SLEEP

Capitalización de mercado: SEK 491.7m

Sleep Cycle Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Sleep Cycle ha aumentado sus beneficios a una tasa media anual de 25.1%, mientras que los beneficios de la industria de Software han experimentado un crecimiento de 22.9% anual. Los ingresos han ido creciendo a una tasa media de 8.7% al año. La rentabilidad financiera de Sleep Cycle es de 58.1%, y sus márgenes netos son de 19.1%.

Información clave

25.11%

Tasa de crecimiento de los beneficios

23.58%

Tasa de crecimiento del BPA

Crecimiento de la industria Software 15.75%
Tasa de crecimiento de los ingresos8.74%
Rentabilidad financiera58.09%
Margen neto19.07%
Próxima actualización de resultados26 Aug 2026

Actualizaciones de resultados anteriores recientes

Recent updates

Actualización de narrativa May 07

SLEEP: Respiratory Research And Sleep Apnea Solution Will Drive Long Term Upside

Analysts have trimmed their price target on Sleep Cycle from SEK30.75 to about SEK28.83, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping the app included in exclusive offerings for Premium, Metal and Ultra customers and giving access to a large, premium user base for its sleep optimization features (Client Announcements).
Artículo de análisis May 02

Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00

It's been a sad week for Sleep Cycle AB (publ) ( STO:SLEEP ), who've watched their investment drop 17% to kr15.34 in...
Actualización de narrativa Apr 21

SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery

Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).
Actualización de narrativa Apr 04

SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential

Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.
Actualización de narrativa Mar 21

SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside

Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.
Actualización de narrativa Mar 06

SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside

Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.
Actualización de narrativa Feb 19

SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside

Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.
Artículo de análisis Feb 09

These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts

One thing we could say about the analysts on Sleep Cycle AB (publ) ( STO:SLEEP ) - they aren't optimistic, having just...
Artículo de análisis Feb 07

Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53

Sleep Cycle AB (publ) ( STO:SLEEP ) is reducing its dividend from last year's comparable payment to SEK0.53 on the 20th...
Actualización de narrativa Feb 04

SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play

Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).
Actualización de narrativa Jan 21

SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside

Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.
Actualización de narrativa Jan 06

SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside

Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).
Artículo de análisis Jan 04

There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings

Sleep Cycle AB (publ)'s ( STO:SLEEP ) price-to-earnings (or "P/E") ratio of 9.2x might make it look like a strong buy...
Actualización de narrativa Dec 15

SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential

Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.
Artículo de análisis Sep 09

Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%

Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a really impressive month, gaining 30% after a shaky period...
Artículo de análisis Aug 27

Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.

The main catalyst behind Sleep Cycle’s upside potential, why JB Hi-Fi might have lost its point of difference, and the bear, base and bull case for Figma.
Actualización de narrativa Aug 23

Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model

Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.
Actualización de narrativa Aug 22

Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities

Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.
Artículo de análisis Apr 30

Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts

As you might know, Sleep Cycle AB (publ) ( STO:SLEEP ) last week released its latest first-quarter, and things did not...
Artículo de análisis Apr 29

The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%

Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a horrible month, losing 34% after a relatively good period...
Artículo de análisis Apr 08

Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00

Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...
User avatar
Nueva narrativa Mar 18

Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships

Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.
Artículo de análisis Mar 06

Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's

Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...
Artículo de análisis Feb 10

Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year

Sleep Cycle AB (publ) ( STO:SLEEP ) will increase its dividend from last year's comparable payment on the 15th of April...
Nueva narrativa Feb 10

Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model

Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device for

Desglose de ingresos y gastos

Cómo gana y gasta dinero Sleep Cycle. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

OM:SLEEP Ingresos, gastos y beneficios (SEK Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Mar 2623645690
31 Dec 2524853690
30 Sep 2525759660
30 Jun 2526162640
31 Mar 2526365610
31 Dec 2426263580
30 Sep 2425656560
30 Jun 2425155520
31 Mar 2424349510
31 Dec 2323646530
30 Sep 2322939590
30 Jun 2322433640
31 Mar 2321833650
31 Dec 2221234610
30 Sep 2220637580
30 Jun 2219934590
31 Mar 2219114650
31 Dec 211838660
30 Sep 211776690
30 Jun 2116812540
31 Mar 2116333420
31 Dec 2015944350
31 Dec 1912342270
31 Dec 189327180

Ingresos de calidad: SLEEP tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(19.1%) de SLEEP son inferiores a los del año pasado (24.7%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lSLEEP han crecido significativamente en un 25.1% al año.

Acelerando crecimiento: SLEEP ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: SLEEP tuvo un crecimiento negativo de los beneficios (-30.8%) durante el año pasado, lo que dificulta la comparación con la media de la industria Software (-11.1%).


Rentabilidad financiera

Alta ROE: La rentabilidad financiera (58.1%) de SLEEP se considera excepcional.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/20 22:28
Precio de las acciones al final del día2026/05/20 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Sleep Cycle AB (publ) está cubierta por 4 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Oscar ErixonCarnegie Investment Bank AB
Erik GranströmDNB Carnegie
Rikard EngbergDNB Carnegie Commissioned Research